Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Piezo1-mediated stellate cell activation causes pressure-induced pancreatic fibrosis in mice
Sandip M. Swain, Joelle M-J Romac, Steven R. Vigna, Rodger A. Liddle
Sandip M. Swain, Joelle M-J Romac, Steven R. Vigna, Rodger A. Liddle
View: Text | PDF
Research Article Gastroenterology

Piezo1-mediated stellate cell activation causes pressure-induced pancreatic fibrosis in mice

  • Text
  • PDF
Abstract

Pancreatic fibrosis is a complication of chronic pancreatitis and is a prominent feature of pancreatic cancer. Pancreatic fibrosis is commonly observed in patients with prolonged pancreatic duct obstruction, which elevates intrapancreatic pressure. We show here that increased pancreatic duct pressure causes fibrosis and describes the mechanism by which pressure increases deposition of extracellular matrix proteins and fibrosis. We found that pancreatic stellate cells (PSCs), the source of the extracellular matrix proteins in fibrosis, express the mechanically activated ion channel Piezo1. By increasing intracellular calcium, mechanical stress or the Piezo1 agonist Yoda1-activated PSCs manifest by loss of perinuclear fat droplets and increased TGF-β1, fibronectin, and type I collagen expression. These effects were blocked by the Piezo1 inhibitor GsMTx4 and absent in PSCs from mice with conditional genetic deletion of Piezo1 in stellate cells, as was pancreatic duct ligation–induced fibrosis. Although TRPV4 has been proposed to have direct mechanosensing properties, we discovered that PSCs from Trpv4-KO mice were protected against Yoda1-triggered activation. Moreover, mice devoid of TRPV4 were protected from pancreatic duct ligation–induced fibrosis. Thus, high pressure within the pancreas stimulates Piezo1 channel opening, and subsequent activation of TRPV4 leads to stellate cell activation and pressure-induced chronic pancreatitis and fibrosis.

Authors

Sandip M. Swain, Joelle M-J Romac, Steven R. Vigna, Rodger A. Liddle

×

Figure 3

Piezo1 agonist, Yoda1, induces stellate cell activation and fibrosis in vitro.

Options: View larger image (or click on image) Download as PowerPoint
Piezo1 agonist, Yoda1, induces stellate cell activation and fibrosis in ...
(A) Fluorescent dye, Bodipy 493/503 stained fat droplets (green) are visible in human PSCs 24 hours after Yoda1 (25 μM). (B) Graph represents the Yoda1-induced loss of fat droplets (from 3 experiments; > 100 cells analyzed for each experiment). (C) Differential interference contrast (DIC) images of human PSCs are shown with or without Yoda1 treatment (25 μM for 24 hr). (D and E) The mean cell area and mean Feret’s diameter (max) of human PSCs with and without Yoda1 (25 μM) (from 3 experiments; > 20 cells analyzed in each experiment). (F and I) Representative images of fibronectin and collagen type I immunostaining in human PSCs 4 days after Yoda1 (25 μM) (from 3 experiments). (G, H, J, and K) mRNA levels of fibronectin, collagen type I, TGF-β1, and Piezo1 in human PSCs 24 hours after treatment with Yoda1 (25 μM) (3–5 experiments). Data are shown as mean ± SEM. Scale bars: 10 μm. Statistical analyses were calculated using 2-tailed Student’s t test for 2 groups, and multiple groups were analyzed by 1-way ANOVA. *P ≤ 0.05; **P ≤ 0.01, ****P ≤ 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts